Overview

T900607 in Treating Patients With Gastroesophageal Junction Cancer

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Seidman Cancer Center
Collaborator:
National Cancer Institute (NCI)